CURRENT BUSINESS MODELS ARE NOT ADJUSTING TO THE TIMES.
Reliable news of any kind is worth big bucks!
Most hemp industry news is from the perspective of the promoter. The hemp industry has an offensive and defensive role to play as a promoter of policies with a vested interest to attract capital even when the risks are intolerable. Creating a viable Business Model from the information available is slanted to attach investors with little regard to the truth or the underlying risks.
Nationwide legalization brought elation to the hemp industry, but it also brought anxiety as CBD manufacturers and retailers await guidance from federal health regulators on how the extract can be incorporated into foods, drugs and cosmetics.
The issue is not fully addressed.
Maybe it's CBD – by far – the largest component of the U.S. hemp industry with billions of dollars already invested cannot afford a panic?
Our proprietary beta algorithm, Greenmark 101, addressed whether an effective Business Model can be designed at this moment of time in the hemp space. The conclusion was "yes with a caveat. " Providing the approach is cost effective with an economic of scale platform focused on gradual, phased-in hemp production with qualified growers to ensure maximum CBD yields and top-end processing for full spectrum isotopes.
At the moment, the industry, on balance, is focused on the "low hanging fruit" without considering the enormous potential in the CBD medicinal space.
However, this truth is never simple. Since now is all there is, our intent to participate must be calculated by combining it with historical and future circumstances. In this manner, our predictive algorithm can be applied as a decision-making tool to design the "best guess" scenario.
Our assumption justifies a Business Model, which embraces the likelihood of material FDA restrictions on CBD use with certifications initiated and successful completed for FDA drug approval and marketing.
The Greenmark 101 algorithm suggests that full spectrum CBD raw material for medicinal purposes would be the primary category with unlimited potential even as more suppliers and competitors occupy the space.
Without addressing the full spectrum CBD raw material for medicinal purposes sector, an effective Business Model is impossible:
The U.S. Food and Drug Administration continually issues reminders that CBD and THC are still not legal to add to food – but promised a further review of its guidelines. “It’s unlawful to introduce food containing added CBD or THC into interstate commerce, or to market CBD or THC products as, or in, dietary supplements, regardless of whether the substances are hemp-derived,” FDA Commissioner Scott Gottlieb wrote. But the agency also acknowledged “substantial public interest in this topic and the clear interest of Congress in fostering the development of appropriate hemp products,” saying it will give the cannabinoid an updated review “in the near future,” with no exact date for an announcement. Gottlieb also announced plans to consult with the CBD industry to develop “predictable and efficient” guidelines. The "consulting part" is all noise.
The 2018 Farm Bill legalized hemp production and guarantees interstate commerce for the plant and “hemp products. But the law also retains the FDA’s authority over how CBD (and hemp-derived THC) can be used.
FDA CANNOT SANCTION CBD AND THC WITHOUT FORMAL DRUG TESTING:
The FDA has repeatedly said that CBD and THC cannot be added to foods, drugs or cosmetics because CBD is an active ingredient in an FDA-approved pharmaceutical, Epidiolex, as well as other medications under review by the federal agency. THC is also off-limits because it is an active ingredient in other drugs under investigation. But the FDA has done little to stop the proliferation of CBD products flooding the marketplace in recent years, beyond sending warning letters to a handful of CBD manufacturers believed to be making illegal medical claims, implying a CBD product can treat or cure a medical ailment. Some states, including California and New York, have followed the FDA’s lead and banned CBD in food. But even in those states, enforcement has been spotty, and CBD is being sold in an ever-growing number of food locations and even stand-alone retail stores that allow product sampling.
Most CBD AND THC PRODUCERS HAVE TAKEN A RECKLESS "CAN'T WAIT" ATTITUDE.
Hemp executives are discounting the agency’s sense of urgency about guiding a fast-growing but largely unregulated industry. The CBD industry is following the lead of the energy drink sector, which was scoffed at for years before it was seen as a mainstream beverage. Twenty-five years ago, when you walked into a retailer and said, ‘Hey, I’m here to sell you an energy drink in a can,’ people literally laughed at you. Fast-forward to now, and it’s a multi-billion-dollar industry that is still growing. … Hemp has been out there a long time, but there are still misconceptions and a lack of education.
Apparently, education the consumer is not the mantra.
Meanwhile, we are advocating that the FDA must be more seriously about cannabis and CBD. They’ve been out to lunch on the entire cannabis movement; a typical dispensary posts at least 30 different medical claims. The FDA must design a comprehensive plan.
We anticipates the agency eventually will set formal limits on over-the-counter CBD products, a move that could allow the sale of dietary supplements alongside stronger pharmaceutical preparations of CBD. FDA is in a difficult position since relaxing guideline of CBD and THC formulations wound scream foul by the 1200+ pharma and companies who are mandated by law to formally test new drugs, file applications that costs multi-millions of dollars, and are required at least 3 years of testing before approval and sales.
Meanwhile, the 1200 pharma and other companies are potential candidates to purchase pure full spectrum CBD, THC and other compounds. The projected markets over ten years may exceed $3.4 trillion, including feeder stocks and drug formulations in 23 classifications.
We have spent a demi-decade investigating mistakes made in the cannabis space, and attempted to understand the best means not to repeat the errors. Our approach was initiated because on the uneven business profiles, shifting regulations and unorthodox trends that made it impossible to create a viable business plan. By incorporating an Evaluation and Assessment Approach (EAA) in our Busness Model, we saved millions of dollars and created a series of workable algorithms that proved phenomenally accurate.
Our newest version, Greenmark 101, is being beta tested to focus exclusively on the extraction/processing categories of marijuana and hemp. The ten month study remains in development mode, but the apparent conclusions appear obvious. Full spectrum CBD raw material for the medicinal sector is a limited risk proposition to enter a billion plus market with a focused Business Model.